A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Cyclacel Pharmaceuticals, Inc.5 sites in 3 countries330 target enrollmentApril 14, 2022

ConditionsSolid Tumor, Adult Lymphoma

InterventionsCYC140

DrugsCYC140

Overview

Phase: Phase 1
Intervention: CYC140
Conditions: Solid Tumor, Adult Lymphoma
Sponsor: Cyclacel Pharmaceuticals, Inc.
Enrollment: 330
Locations: 5
Primary Endpoint: Maximum tolerated dose
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.

Detailed Description

Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups: Group 1: Bladder cancer Group 2: Breast cancer: Triple-negative breast cancer (TNBC) Group 3: Lung cancer (non-small cell lung cancer \[NSCLC\] and small cell lung cancer \[SCLC\]) Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) Group 7: T-cell lymphoma (cutaneous T-cell lymphoma \[CTCL\] and peripheral T-cell lymphoma \[PTCL\]) Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers

Registry

clinicaltrials.gov

Start Date

April 14, 2022

End Date

November 2025

Last Updated

2 years ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Cyclacel Pharmaceuticals, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Males or females aged ≥ 18 years.
•Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
•For Phase 1, all tumor types may be enrolled
•For Phase 2, subjects will be enrolled as per the study design section above
•ECOG performance status of 0-
•Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
•Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
•Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
•Able to agree to and sign the informed consent and to comply with the protocol.

Exclusion Criteria

•Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
•Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-
•Subjects with a history of another primary malignancy, other than:
•In situ carcinomas, e.g., breast, cervix, and prostate
•Locally excised nonmelanoma skin cancer
•No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
•Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
•Diseases that significantly affect GI absorption of CYC
•Subjects who have impaired cardiac function or clinically significant cardiac disease.
•Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment

Arms & Interventions

Phase 1 Dose Escalation

Phase 1 = CYC140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.

Intervention: CYC140